Hwang, Michael S.
Miller, Michelle S. http://orcid.org/0000-0003-1972-4503
Thirawatananond, Puchong
Douglass, Jacqueline http://orcid.org/0000-0002-9113-7090
Wright, Katharine M. http://orcid.org/0000-0001-9060-3849
Hsiue, Emily Han-Chung
Mog, Brian J. http://orcid.org/0000-0001-9988-7147
Aytenfisu, Tihitina Y.
Murphy, Michael B.
Aitana Azurmendi, P. http://orcid.org/0000-0001-8979-641X
Skora, Andrew D.
Pearlman, Alexander H. http://orcid.org/0000-0002-3504-7517
Paul, Suman http://orcid.org/0000-0001-9357-3702
DiNapoli, Sarah R. http://orcid.org/0000-0002-3675-9030
Konig, Maximilian F. http://orcid.org/0000-0001-5045-5255
Bettegowda, Chetan
Pardoll, Drew M.
Papadopoulos, Nickolas http://orcid.org/0000-0001-7135-7451
Kinzler, Kenneth W.
Vogelstein, Bert http://orcid.org/0000-0003-0766-3854
Zhou, Shibin http://orcid.org/0000-0003-1941-4425
Gabelli, Sandra B. http://orcid.org/0000-0003-1205-5204
Funding for this research was provided by:
Lustgarten Foundation
Commonwealth Fund
Burroughs Wellcome Fund
Article History
Received: 22 December 2020
Accepted: 16 August 2021
First Online: 6 September 2021
Competing interests
: B.V., K.W.K., and N.P. are founders of Thrive Earlier Detection. K.W.K. and N.P. are consultants to and were on the Board of Directors of Thrive Earlier Detection. B.V., K.W.K., N.P., and S.Z. own equity in Exact Sciences. B.V., K.W.K., N.P., S.Z., and D.M.P. are founders of and serve or may serve as consultants to ManaT Bio, and hold or may hold equity in ManaT Holdings, LLC. B.V., K.W.K., N.P., and S.Z. are founders of, hold equity in, and serve as consultants to Personal Genome Diagnostics. S.Z. has a research agreement with BioMed Valley Discoveries. S.B.G. is a founder and holds equity in AMS. K.W.K. and B.V. are consultants to Sysmex, Eisai, and CAGE Pharma and hold equity in CAGE Pharma. B.V. is also a consultant to Catalio. K.W.K., B.V., S.Z., and N.P. are consultants to and hold equity in NeoPhore. N.P. is an advisor to and holds equity in CAGE Pharma. C.B. is a consultant to Depuy-Synthes and Bionaut Pharmaceuticals. The companies named above, as well as other companies, have licensed previously described technologies related to the work described in this paper from Johns Hopkins University. B.V., K.W.K., S.Z., N.P., and C.B. are inventors on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. The terms of all these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies. M.F.K. received personal fees from Bristol Myers Squibb and Celltrion. D.M.P. reports grant and patent royalties through institution from Bristol Myers Squibb, grant from Compugen, stock from Trieza Therapeutics and Dracen Pharmaceuticals, and founder equity from Potenza; being a consultant for Aduro Biotech, Amgen, AstraZeneca (MedImmune/Amplimmune), Bayer, DNAtrix, Dynavax Technologies Corporation, Ervaxx, FLX Bio, Rock Springs Capital, Janssen, Merck, Tizona, and Immunomic Therapeutics; being on the scientific advisory board of Five Prime Therapeutics, Camden Nexus II, WindMIL; and being on the board of directors for Dracen Pharmaceuticals. The remaining authors declare no competing interests.